Idraparinux sodium. Sanofi-Aventis.
Idraparinux sodium, a long-acting anti-Factor Xa synthetic pentasaccharide, is under development by Sanofi-Aventis for the potential prevention and treatment of venous thromboembolic events in patients with deep vein thrombosis or pulmonary embolism.
Ma
Qing
Q
University at Buffalo, The State University of New York, School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice, Buffalo, NY 14260, USA. qingma@buffalo.edu
Fareed
Jawed
J
D000818:Animals; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D009844:Oligosaccharides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D013927:Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
D005343:Fibrinolytic Agents; D009844:Oligosaccharides; C479958:idraparinux